Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Elosulfase Alfa

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 7Vimizim

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Vimizim

    Elosulfase Alfa

    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Brand Name : Vimizim

    U.S.A
    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Biomarin

    Elosulfase Alfa

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2020 Revenue in Millions : 544

    2019 Revenue in Millions : 544

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Vimizim

    Elosulfase Alfa

    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Brand Name : Vimizim

    U.S.A
    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Biomarin

    Elosulfase Alfa

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2021 Revenue in Millions : 623

    2020 Revenue in Millions : 544

    Growth (%) : 14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Vimizim

    Elosulfase Alfa

    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Brand Name : Vimizim

    U.S.A
    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Biomarin

    Elosulfase Alfa

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2022 Revenue in Millions : 664

    2021 Revenue in Millions : 623

    Growth (%) : 7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Vimizim

    Elosulfase Alfa

    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Brand Name : Vimizim

    U.S.A
    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Biomarin

    Elosulfase Alfa

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2023 Revenue in Millions : 701

    2022 Revenue in Millions : 664

    Growth (%) : 6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Vimizim

    Elosulfase Alfa

    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Brand Name : Vimizim

    U.S.A
    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Biomarin

    Elosulfase Alfa

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2017 Revenue in Millions : 413

    2016 Revenue in Millions : 354

    Growth (%) : 17

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Vimizim

    Elosulfase Alfa

    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Brand Name : Vimizim

    U.S.A
    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Biomarin

    Elosulfase Alfa

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2018 Revenue in Millions : 482

    2017 Revenue in Millions : 413

    Growth (%) : 17%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Vimizim

    Elosulfase Alfa

    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Brand Name : Vimizim

    U.S.A
    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Biomarin

    Elosulfase Alfa

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2019 Revenue in Millions : 544

    2018 Revenue in Millions : 482

    Growth (%) : 13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF